SCHEMBL4335442

SCHEMBL4335442

Cc1ccccc1CN1CCN(c2ccc(/C=N/NC(N)=S)c(F)c2F)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.42
ALDH1A1 P00352 5/20 0.40
MAPT P10636 4/20 0.40
ALOX12 P18054 3/20 0.40
TDP1 Q9NUW8 2/20 0.40
KDM4E B2RXH2 3/20 0.39
KMT2A Q03164 2/20 0.39
LMNA P02545 2/20 0.39
TRPC5 Q9UL62 2/20 0.38
HTR7 P34969 1/20 0.38
RAB9A P51151 2/20 0.38
POLB P06746 1/20 0.38
CASP3 P42574 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
SENP6 Q9GZR1 1/20 0.38
GAA P10253 6/20 0.38
NPSR1 Q6W5P4 4/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4335444 1.00 MAOB (0.42) MAOBALDH1A1MAPTALOX12TDP1
SCHEMBL4459407 0.90 MAOB (0.49) MAOBALDH1A1MAPTKDM4EKMT2A
SCHEMBL4459405 0.90 MAOB (0.49) MAOBALDH1A1MAPTKDM4EKMT2A
SCHEMBL4344613 0.89 ALDH1A1 (0.48) MAOBALDH1A1MAPTTDP1KDM4E
SCHEMBL4344610 0.89 ALDH1A1 (0.48) MAOBALDH1A1MAPTTDP1KDM4E
SCHEMBL4329805 0.88 KDM4E (0.47) ALDH1A1MAPTTDP1KDM4EKMT2A
SCHEMBL4329803 0.88 KDM4E (0.47) ALDH1A1MAPTTDP1KDM4EKMT2A
SCHEMBL4323793 0.86 MAOB (0.45) MAOBALDH1A1MAPTALOX12TDP1
SCHEMBL4323796 0.86 MAOB (0.45) MAOBALDH1A1MAPTALOX12TDP1
SCHEMBL4322538 0.86 L3MBTL1 (0.49) MAOBALDH1A1ALOX12KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAOB 2762/4885ALDH1A1 1459/4885MAPT 3619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.